Event-Driven Stocks

Kite Pharma, Inc.

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

Signs● 4 good● 3 warningdetails ↓

Financials

SEC XBRL · annual
 FY16FY15FY14FY13
Revenue$5.1M$2.9M$0—
Operating income−$46.0M−$15.6M−$3.2M−$6.4M
Net income−$267.1M−$101.7M−$42.6M−$6.4M
Total assets$524.3M$708.0M$370.8M$23.0M
Total liabilities$96.3M$92.2M$8.2M$1.4M
Equity$428.0M$615.8M$362.6M$21.6M
EPS (diluted)————
Shares out.48.8M42.5M41.9M5.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2016
Operating margin
−896.6%
Net margin
−5209.1%
Return on equity
−62.4%
Return on assets
−50.9%
Return on capital (ROCE)
−9.8%
Liabilities / assets
18.4%
Debt / equity
0.23×
Book value / share
$8.76
Revenue growth (YoY)
78.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2016
Altman Z″ (distress)
6.08safe
Accruals / assets
−18.7%clean
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
60
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 3 warning● 4 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
1 acquisitions11 disposalsnet −122,302 shares · last 12
InsiderDateTypeSharesPrice
Peacock Jonathan MDirectorSep 13, 2017Gift635$0.00
Clark Ian TDirectorOct 3, 2017U1,776$180.00
Nussbaum RanDirectorOct 3, 2017D4,360—
Kazam Joshua ADirectorSep 28, 2017J70,050$0.00
Humer Franz BDirectorOct 3, 2017U4,624$180.00
Doumani RoyDirectorOct 3, 2017U150,620$180.00
Bonderman DavidDirectorOct 3, 2017D4,360—
Ruchefsky Steven BDirectorSep 14, 2017Gift2,250$0.00
Champsi FarahDirectorSep 29, 2017Gift2,800$0.00
Witte Owen N.DirectorSep 18, 2017Gift12,000$0.00
Moore Timothy L.Officer — EVP, Technical OperationsOct 3, 2017U3,927$180.00
Tomasello ShawnOfficer — Chief Commercial OfficerSep 25, 2017Gift5,000$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)